Carlos L. Arteaga, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, discusses the CALGB 40603 trial that examined the neoadjuvant treatment of triple-negative breast cancer (TNBC).
In the study, patients with TNBC were randomized to receive the neoadjuvant standard of care with or without carboplatin, a DNA damaging chemotherapy. By adding carboplatin to the standard of care, the rate of pathologic complete response (pCR) was improved, Arteaga says. Additionally, the rate of pCR in this study could translate into a long-term improvement in outcomes.
<<< View more from the 2013 SABCS Meeting